[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100633795":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":10,"centralContacts":20,"locations":26,"responsibleParty":140,"collaborators":142,"id":158,"slug":159,"hasResults":160,"nctId":161,"briefTitle":162,"officialTitle":162,"acronym":163,"eligibilityCriteria":164,"healthyVolunteers":160,"sex":165,"minAge":166,"maxAge":10,"enrollmentInfo":167,"targetDuration":10,"studyType":170,"phases":10,"briefSummary":171,"conditions":172,"keywords":176,"overallStatus":29,"whyStopped":10,"lastUpdateSubmitDate":182,"lastUpdatePostDateStruct":183,"startDateStruct":186,"completionDateStruct":188,"leadSponsor":190,"locationsCount":191},{"fullName":5,"class":6},"Xijing Hospital","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Study Cohort",null,"All enrolled patients with suspected prostate cancer undergo both standard and delayed PSMA PET imaging. Each patient serves as their own control, with diagnostic performance compared between the standard imaging phase and the delayed imaging phase.",[13],"Diagnostic Test: [⁶⁸Ga]Ga-PSMA PET\u002FCT with Delayed Pelvic PET-Only Acquisition",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":10},"DIAGNOSTIC_TEST","[⁶⁸Ga]Ga-PSMA PET\u002FCT with Delayed Pelvic PET-Only Acquisition","All enrolled patients undergo a dual-phase PSMA PET\u002FCT imaging protocol consisting of: (1) a standard whole-body PET\u002FCT acquisition performed at approximately 60 minutes after intravenous administration of \\[⁶⁸Ga\\]Ga-PSMA-11; and (2) a delayed pelvic PET acquisition performed at approximately 2-3 hours post-injection (exact timing to be standardized across participating centers based on local protocols and clinical workflow). The delayed phase does not include a separate CT scan; images are reconstructed using the CT dataset obtained from the initial whole-body acquisition for attenuation correction.",[9],[21],{"name":22,"role":23,"phone":24,"phoneExt":10,"email":25},"Jianhua Jiao, MD.","CONTACT","+86 18700919857","1531769428@qq.com",[27,45,59,72,85,99,107,116,128],{"facility":28,"status":29,"city":30,"state":31,"zip":10,"country":32,"countryCode":33,"cosmosGeoPoint":34,"geoPoint":39,"contacts":40},"The First Hospital of Lanzhou University","RECRUITING","Lanzhou","Gansu","China","CN",{"type":35,"coordinates":36},"Point",[37,38],103.83987,36.05701,{"lat":38,"lon":37},[41,43],{"name":42,"role":23,"phone":24,"phoneExt":10,"email":25},"Wei Zhang, MD.",{"name":42,"role":44,"phone":10,"phoneExt":10,"email":10},"PRINCIPAL_INVESTIGATOR",{"facility":46,"status":29,"city":47,"state":48,"zip":10,"country":32,"countryCode":33,"cosmosGeoPoint":49,"geoPoint":53,"contacts":54},"General Hospital of Ningxia Medical University","Yinchuan","Ningxia",{"type":35,"coordinates":50},[51,52],106.27306,38.46806,{"lat":52,"lon":51},[55,57],{"name":56,"role":23,"phone":24,"phoneExt":10,"email":25},"Zhiyong Lv",{"name":58,"role":44,"phone":10,"phoneExt":10,"email":10},"Zhiyong Lv, MD.",{"facility":60,"status":29,"city":61,"state":62,"zip":10,"country":32,"countryCode":33,"cosmosGeoPoint":63,"geoPoint":67,"contacts":68},"Qinghai University Affiliated Hospital","Xining","Qinghai",{"type":35,"coordinates":64},[65,66],101.75739,36.62554,{"lat":66,"lon":65},[69,71],{"name":70,"role":23,"phone":24,"phoneExt":10,"email":25},"Guojun Chen, MD.",{"name":70,"role":44,"phone":10,"phoneExt":10,"email":10},{"facility":73,"status":29,"city":74,"state":75,"zip":10,"country":32,"countryCode":33,"cosmosGeoPoint":76,"geoPoint":80,"contacts":81},"Weinan Central Hospita","Weinan","Shaanxi",{"type":35,"coordinates":77},[78,79],109.50891,34.50355,{"lat":79,"lon":78},[82,84],{"name":83,"role":23,"phone":24,"phoneExt":10,"email":25},"Weihong Zhao, MD.",{"name":83,"role":44,"phone":10,"phoneExt":10,"email":10},{"facility":86,"status":29,"city":87,"state":75,"zip":88,"country":32,"countryCode":33,"cosmosGeoPoint":89,"geoPoint":93,"contacts":94},"Xijing 986 Hospital","Xi'an","710032",{"type":35,"coordinates":90},[91,92],108.92861,34.25833,{"lat":92,"lon":91},[95,97],{"name":96,"role":23,"phone":24,"phoneExt":10,"email":25},"Wuhe Zhang",{"name":98,"role":44,"phone":10,"phoneExt":10,"email":10},"Wuhe Zhang, MD.",{"facility":5,"status":29,"city":87,"state":75,"zip":88,"country":32,"countryCode":33,"cosmosGeoPoint":100,"geoPoint":102,"contacts":103},{"type":35,"coordinates":101},[91,92],{"lat":92,"lon":91},[104,105],{"name":22,"role":23,"phone":24,"phoneExt":10,"email":25},{"name":106,"role":44,"phone":10,"phoneExt":10,"email":10},"Weijun Qin, MD.",{"facility":108,"status":29,"city":87,"state":75,"zip":10,"country":32,"countryCode":33,"cosmosGeoPoint":109,"geoPoint":111,"contacts":112},"Shaanxi Provincial People's Hospital",{"type":35,"coordinates":110},[91,92],{"lat":92,"lon":91},[113,115],{"name":114,"role":23,"phone":24,"phoneExt":10,"email":25},"Yi Sun, MD.",{"name":114,"role":44,"phone":10,"phoneExt":10,"email":10},{"facility":117,"status":29,"city":118,"state":75,"zip":10,"country":32,"countryCode":33,"cosmosGeoPoint":119,"geoPoint":123,"contacts":124},"The Second Affiliated Hospital of Shaanxi University of Chinese Medicine","Xianyang",{"type":35,"coordinates":120},[121,122],108.70261,34.33778,{"lat":122,"lon":121},[125,127],{"name":126,"role":23,"phone":24,"phoneExt":10,"email":25},"Wei Zheng, MD.",{"name":126,"role":44,"phone":10,"phoneExt":10,"email":10},{"facility":129,"status":29,"city":130,"state":75,"zip":10,"country":32,"countryCode":33,"cosmosGeoPoint":131,"geoPoint":135,"contacts":136},"Affiliated Hospital of Yan'an University","Yan’an",{"type":35,"coordinates":132},[133,134],109.49167,36.59889,{"lat":134,"lon":133},[137,139],{"name":138,"role":23,"phone":24,"phoneExt":10,"email":25},"Jixue Gao, MD.",{"name":138,"role":44,"phone":10,"phoneExt":10,"email":10},{"type":141,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR",[143,145,147,148,150,152,153,155,157],{"name":144,"class":6},"Air Force Military Medical University, China",{"name":146,"class":6},"National Translational Science Center for Molecular Medicine",{"name":108,"class":6},{"name":149,"class":6},"Weinan Central Hospital",{"name":151,"class":6},"Yan'an University Affiliated Hospital",{"name":117,"class":6},{"name":154,"class":6},"LanZhou University",{"name":156,"class":6},"Affiliated Hospital of Qinghai University",{"name":46,"class":6},"100633795","delayed-psma-petct-imaging-for-diagnosing-clinically-significant-prostate-cancer-in-biopsy-nave-men-with-suspected-prostate-cancer-100633795",false,"NCT07531329","Delayed PSMA PET\u002FCT Imaging for Diagnosing Clinically Significant Prostate Cancer in Biopsy-Naïve Men With Suspected Prostate Cancer","DEPICT","Inclusion Criteria:\n\n1. Patients with suspected prostate cancer and a PSA level ≥4.0 ng\u002FmL\n2. Patients who undergo PSMA PET imaging (including delayed phase imaging) prior to prostate biopsy\n3. Patients who are willing to undergo prostate biopsy\n4. Patients who provide written informed consent to participate in the study\n\nExclusion Criteria:\n\n1. Patients who have received any prior prostate cancer-related treatment before the initial PSMA PET scan\n2. Patients with a history of other malignancies within the past two years\n3. Patients judged by the study investigator to be at risk for serious complications that could interfere with the normal conduct of the study","MALE","18 Years",{"count":168,"type":169},1000,"ESTIMATED","OBSERVATIONAL","Brief Summary This prospective, multicenter study evaluates whether delayed PSMA PET imaging improves diagnostic efficacy for detecting clinically significant prostate cancer (Gleason score ≥7) compared with standard imaging in patients with suspected newly diagnosed prostate cancer. Each patient serves as their own control, with diagnostic performance compared between standard (60-minute) and delayed (2-3 hour) acquisitions.\n\nBackground PSMA PET has transformed prostate cancer imaging, with emerging evidence suggesting delayed acquisition may further improve diagnostic accuracy by increasing tumor-to-background ratio. Recent studies demonstrate that delayed imaging significantly reduces equivocal findings and enhances detection of clinically significant prostate cancer.\n\nNeed While standard PSMA PET is well-validated, prospective multicenter data specifically evaluating the incremental diagnostic value of delayed imaging for clinically significant prostate cancer in treatment-naïve patients are lacking. This study addresses this gap by systematically comparing standard and delayed imaging in a large, well-defined cohort.\n\nPrimary Outcome The primary outcome is to compare the area under the curve (AUC) of delayed SUVmax versus standard SUVmax for detecting clinically significant prostate cancer (csPCa), and to determine whether delayed imaging is superior to standard imaging.\n\nSecondary Outcomes\n\n1. Optimal diagnostic thresholds for delayed imaging\n\n   1. Determine the optimal threshold for delayed SUVmax using ROC analysis with the Youden index;\n   2. Determine the optimal threshold for ΔSUVmax (delayed minus standard SUVmax);\n   3. Validate the sensitivity, specificity, and AUC of these thresholds in an independent validation set.\n2. Biopsy avoidance potential In patients with PI RADS 4-5 lesions, calculate the negative predictive value (NPV) using a predefined high threshold to estimate the proportion who could safely avoid biopsy.\n3. Diagnostic performance in key subgroups Compare the AUC of delayed SUVmax versus standard SUVmax for csPCa detection in patients with PI RADS 2-3 and in those with PI RADS 4-5.\n4. Additional lesion detection Proportion of patients with additional csPCa lesions detected only on delayed imaging, and the proportion whose PI RADS category would be upgraded based on these findings.\n5. Clinical decision impact Proportion of patients in whom management recommendations would change after incorporating delayed imaging results, compared with standard imaging alone.\n6. Exploratory subgroup analyses Stratify by PSA level (\\\u003C4, 4 10, \\>10 ng\u002FmL) and PSA density (\\\u003C0.10, 0.10-0.20, \\>0.20 ng\u002FmL\u002Fcc) to identify subgroups that derive the greatest benefit from delayed imaging; additionally, explore combined subgroups such as PI RADS 3 with PSA 4-10 or PSAD 0.10-0.20.\n\nInclusion Criteria\n\n1. Suspected prostate cancer based on elevated PSA (≥4.0 ng\u002FmL) or clinical symptoms\n2. Undergo PSMA PET (standard + delayed) prior to prostate biopsy\n3. Willing to undergo prostate biopsy\n4. Provide written informed consent Exclusion Criteria\n\n1\\. Prior prostate cancer treatment before PSMA PET imaging 2. Other malignancy within past two years 3. Investigator-judged risk of serious complications interfering with study conduct",[173,174,175],"Treatment-naive Prostate Cancer","Suspected Prostate Cancer","Molecular Imaging",[177,178,179,180,181],"Prostate Cancer","PSMA PET","Delayed imaging","Diagnostic","Efficacy","2026-04-08",{"date":184,"type":185},"2026-04-15","ACTUAL",{"date":187,"type":185},"2021-03-05",{"date":189,"type":169},"2028-03-05",{"name":5,"class":6},9]